MRNA
Moderna Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
Actual EPS |
---|
Consensus EPS |
Estimated EPS |
Number of Estimates |
EPS Surprise |
Stats
Summary
moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a
Market Cap: 37.5 Billion
Primary Exchange: NASDAQ
Website: https://www.modernatx.com/
Shares Outstanding: 382 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.1525732946213858
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Ethical Flags
Longest drawdown: 808 trading days
From: 2021-08-09 To: 2024-03-07
Lowest Point:
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2019 Update
via: SeekingAlpha at 2019-06-12 01:06:09:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Ole Andreas Halvorsen… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2019 Update
via: SeekingAlpha at 2019-06-12 01:06:09:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Ole Andreas Halvorsen… read more...
Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
---|
Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
---|